The DOI matches its Crossref record.
Long–Term Follow–Up of Interferon Alfa Treatment in Chinese Patients With Chronic Hepatitis B Infection: the Effect on Hepatitis B E Antigen Seroconversion and the Development of Cirrhosis–Related Complications
Abstract
The long–term effect of interferon alfa (IFN–α) in Chinese patients with chronic hepatitis B infection is unknown. A total of 411 chronic hepatitis B patients (208 treated with IFN–α and 203 as control) were followed up for hepatitis B serology and the development of hepatoma and other cirrhosis–related complications. The hepatitis B e antigen (HBeAg) seroconversion rate in the IFN–α-treated group, though significantly greater at 6 and 24 months, was comparable with the control group on subsequent follow–up, irrespective of pretreatment alanine transaminase (ALT) levels. HBeAg seroreversion rate was higher in the IFN–α group compared with the control group (21.1% vs. 2.2%; P = .001). Loss of hepatitis B surface antigen (HBsAg) occurred in 2.4% of the IFN–α-treated patients and 0.49% of the control patients (P = NS). Around 90% of the anti–HBe-positive patients in both groups were still hepatitis B virus (HBV)–DNA-positive by polymerase chain reaction (PCR) assay. Two patients suffered from hepatic reactivation during the course of treatment. Nine (4.3%) patients in the IFN–α group and 2 (1.0%) in the control group developed complications of cirrhosis and hepatoma (P = .062). In Chinese HBsAg carriers, IFN–α was of no long–term benefit in inducing HBeAg seroconversion or in the prevention of hepatoma and other cirrhosis–related complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Yim, H. J., & Lok, A. S.-F. (2006) · Hepatology · doi:10.1002/hep.20956 · Cited by 545
Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S., & Lok, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.035 · Cited by 459
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Sánchez-Tapias, J. M., Costa, J., Mas, A., Bruguera, M., & Rodés, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.37041 · Cited by 415
Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications
Yuen, M.-F., Yuan, H.-J., Wong, D. K.-H., Yuen, J. C.-H., Wong, W.-M., Chan, A. O.-O., Wong, B. C.-Y., Lai, K.-C., & Lai, C.-L. (2005) · Gut · doi:10.1136/gut.2005.065136 · Cited by 375
Self-citationKeeffe, E. B., Dieterich, D. T., Han, S. B., Jacobson, I. M., Martin, P., Schiff, E. R., Tobias, H., & Wright, T. L. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.05.016 · Cited by 374
Epidemiology and natural history of hepatocellular carcinoma
McGlynn, K. A., & London, W. T. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2004.10.004 · Cited by 373
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
SUNG, J. J. Y., TSOI, K. K. F., WONG, V. W. S., LI, K. C. T., & CHAN, H. L. Y. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03816.x · Cited by 370
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States
Keeffe, E. B., Dieterich, D. T., Han, S.-H. B., Jacobson, I. M., Martin, P., Schiff, E. R., Tobias, H., & Wright, T. L. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00312-4 · Cited by 359
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
van Zonneveld, M., Honkoop, P., Hansen, B. E., Niesters, H. G. M., Murad, S. D., de Man, R. A., Schalm, S. W., & Janssen, H. L. A. (2004) · Hepatology · doi:10.1002/hep.20128 · Cited by 322
Liu, J., Yang, H., Lee, M., Lu, S., Jen, C., Wang, L., You, S., Iloeje, U. H., & Chen, C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.048 · Cited by 265
Yuen, M.-F., Seto, W.-K., Chow, D. H.-F., Tsui, K., Wong, D. K.-H., Ngai, V. W.-S., Wong, B. C.-Y., Fung, J., Yuen, J. C.-H., & Lai, C.-L. (2007) · Antiviral Therapy · doi:10.1177/135965350701200816 · Cited by 257
Self-citationMortality from cirrhosis: lack of progress over the last 35 years
Gluud, C. (2005) · Gut · doi:10.1136/gut.2005.072876 · Cited by 17
Metadata
- Authors
- Yuen, M.-F., Hui, C.-K., Cheng, C.-C., Wu, C.-H., Lai, Y.-P., & Lai, C.-L.
- Venue
- Hepatology
- Published
- 2001-07
- Volume
- 34
- Issue
- 1
- Pages
- 139-145
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2102245402
- Cited by
- 232
- References
- 0
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.